Optimizing the safety of biologic therapy for IBD

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Biologic therapies have transformed inflammatory bowel disease (IBD) management.
• These advanced treatments, however, are associated with significant safety concerns.

Purpose of the Study:

• To outline strategies for minimizing risks associated with biologic therapies in IBD.
• To emphasize proactive and reactive measures for patient safety.

Main Methods:

• Review of established and recommended safety protocols for biologic therapy.
• Discussion of pretreatment screening, vaccination, and ongoing monitoring strategies.
• Highlighting the importance of patient and physician education.

Main Results:

• Pretreatment strategies include thorough patient history, physical examination, and screening for latent tuberculosis and sepsis.
• Vaccination against preventable diseases is recommended prior to initiating therapy.
• Close patient monitoring during treatment and early intervention for adverse events are crucial.

Conclusions:

• Implementing comprehensive safety strategies is essential for the effective use of biologic therapies in IBD.
• Proactive risk management, including screening, vaccination, and vigilant monitoring, improves patient outcomes.
• Educating both physicians and patients facilitates early detection and management of adverse events.